We focus on the development of novel medicines using our proprietary Extreme Genetics® platform.
We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.
Shutting Down Pain
Xenon featured in Genentech’s Big Ideas animated short
April 2, 2015 – Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
March 16, 2015 – Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors
March 12, 2015 – Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update